Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: A Southwest Oncology Group study

Journal of Clinical Oncology

Volumn 15, Issue 6, 1997, Pages 2414-2419

  Whitehead, Robert P ^a   Jacobson, Joth ^a   Brown, Thomas D ^a   Taylor, Sarah A ^a   Weiss, Geoffrey R ^a   Macdonald, John S ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PANCREAS ADENOCARCINOMA; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; VOMITING;

EID: 0030900150     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.6.2414     Document Type: Article

References (29)

1. Parker SI, Tong T, Bolden S, et al: Cancer statistics 1996. CA 65:5-27, 1996
2. Schein PS: The role of chemotherapy in the management of gastric and pancreatic carcinomas. Semin Oncol 12:49-60, 1985 (suppl 6)
3. Schnoll SF, Macdonald JS: Chemotherapy of adenocarcinoma of the pancreas. Semin Oncol 23:220-228, 1996
4. Casper ES, Green MR, Kelsen DP, et al: Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12:29-34, 1994
5. Moore M, Andersen J, Burris H, et al: A randomized trial of gemcitabine versus 5FU as first-line therapy in advanced pancreatic cancer. Proc Am Soc Clin Oncol 14:199, 1995 (abstr)
6. Rowinsky EK, Onetto N, Canetta RM, et al: Taxol: The first of the taxanes, an important new class of antitumor agents. Semin Oncol 19:646-662, 1992
7. Ettinger DS: Overview of paclitaxel (Taxol) in advanced lung cancer. Semin Oncol 20:46-49, 1993 (suppl 3)
8. Forastiere AA: Paclitaxel (Taxol) for the treatment of head and neck cancer. Semin Oncol 21:49-52, 1994 (suppl 8)
9. Kelsen D, Ajani J, Ilson D, et al: A phase II trial of paclitaxel (Taxol) in advanced esophageal cancer: A preliminary report. Semin Oncol 21:44-48, 1994 (suppl 8)
10. Rowinsky EK, Donehower RC: Paclitaxel (Taxol). N Engl J Med 332:1004-1014, 1995
11. Roth BJ, Yeap BY, Wilding G, et al: Taxol in advanced, hormone-refractory carcinoma of the prostate, a phase II trial of the Eastern Cooperative Oncology Group. Cancer 72:2457-2460, 1993
12. Einzig AI, Gorowski E, Sasloff J, et al: Phase II trial of Taxol in patients with metastatic renal cell carcinoma. Cancer Invest 9:133-136, 1991
13. Jones DV Jr, Lozano R, Hogue A, et al: Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. J Clin Oncol 14:2306-2310, 1996
14. Einzig AI, Wiernik PH, Lipsitz S, et al: Phase II trial of Taxol in patients with adenocarcinoma of the upper gastrointestinal tract: The Eastern Cooperative Oncology Group (ECOG) results. Proc Am Soc Clin Oncol 12:194, 1993 (abstr)
15. Rothenberg ML, Burris HA III, Andersen JS, et al: Gemcitabine: Effective palliative therapy for pancreas cancer patients failing 5FU. Proc Am Soc Clin Oncol 14:198, 1995 (abstr)
16. Moore M, Andersen J, Burris H, et al: A randomized trial of gemcitabine versus 5FU as first-line therapy in advanced pancreatic cancer. Proc Am Soc Clin Oncol 14:199, 1995 (abstr)
17. Eisenhauer EA, ten Bakkel Huinink WW, Swenerton KD, et al: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 12:2654-2666, 1994
18. Löffler TM, Freund W, Lipke J, et al: Schedule -and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: Results of a phase I/II trial. Semin Oncol 23:32-34, 1996 (suppl 16)
19. Gabrilove JL, Jakubowski A, Scher H, et al: Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318:1414-1422, 1988
20. Kohn EC, Sarosy G, Bicher A, et al: Dose-intense Taxol: High response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 86:18-24, 1994
21. Link CJ Jr, Bicher A, Kohn EC, et al: Flexible granulocyte colony-stimulating factor dosing in ovarian cancer patients who receive dose-intense Taxol therapy. Blood 83:1188-1192, 1994
22. Omura GA, Brady MF, Delmore JE, et al: A randomized trial of paclitaxel at 2 dose levels and filgrastim at 2 doses in platinum pretreated epithelial ovarian cancer: A Gynecologic Oncology Group, SWOG, NCCTG, and ECOG study. Proc Am Soc Clin Oncol 15:280, 1996 (abstr)
23. Rougier P, De Forni M, Adenis A, et al: Phase II study of Taxotere (RP56976, docetaxel) in pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 13:200, 1994 (abstr)
24. Abbruzzese JL, Evans D, Gravel D, et al: Docetaxel, a potentially active agent for patients with pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 14:221, 1995 (abstr)
25. Valero V, Burris HA III, Jones SE, et al: Multicenter pilot study of Taxotere in Taxol-resistant metastatic breast cancer. Proc Am Soc Clin Oncol 15:107, 1996 (abstr)
26. Wils JA, Kok T, Wagener DJ, et al: Activity of cisplatin in adenocarcinoma of the pancreas. Eur J Cancer 29A:203-204, 1993
27. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996
28. Rowinsky EK, Gilbert MR, McGuire WP, et al: Sequences of Taxol and cisplatin: A phase I and pharmacologic study. J Clin Oncol 9:1692-1703, 1991
29. Cornelison TL, Goldberg JM, Fiver MS: Taxol and platinum chemotherapy in the treatment of pancreatic and jejunal carcinoma. J Surg Oncol 59:204-208, 1995